Literature DB >> 17526010

Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma.

Christine Mauz-Körholz1, Stephanie Gorde-Grosjean, Dirk Hasenclever, Ananth Shankar, Wolfgang Dörffel, W Hamish Wallace, Günther Schellong, Alain Robert, Dieter Körholz, Odile Oberlin, Georgina W Hall, Judith Landman-Parker.   

Abstract

BACKGROUND: Lymphocyte-predominant Hodgkin lymphoma (LPHL) is a rare, CD20-positive, good prognostic lymphoma in children. Patients with early-stage LPHL who underwent successful surgical lymph node resection alone have been reported. To clarify the optimum treatment strategy in children, European study groups were asked to report their experience of surgery alone used in the treatment of pediatric LPHL.
METHODS: Data from 58 patients were collected by the French Society for Pediatric Cancers, the German-Austrian Pediatric Study Group/German Society of Pediatric Oncology and Hematology (Germany), and the Children's Cancer and Leukaemia Group (United Kingdom). In total, there were 50 boys and 8 girls, and the median age was 11 years (age range, 4-17 years). Fifty-four patients had stage IA disease, 2 patients had stage IIA disease, and 2 patients had stage IIIA disease.
RESULTS: With a median follow-up of 43 months (range, 2-202 months), the overall survival rate was 100%, and the progression-free survival (PFS) rate was 57%. Fifty-one of 58 patients achieved complete remission (CR) after surgery. In the CR group, the overall PFS rate was 67% (95% confidence interval, 51-82%). All seven patients who had residual disease after initial surgery developed recurrences (P = .003). Among 18 patients with stage IA LPHL who developed recurrent disease, 11 patients had local recurrences, and 7 patients recurred in stage IIA. One patient with stage IIIA disease presented with high-grade B-cell non-Hodgkin lymphoma at 10 years of follow-up.
CONCLUSIONS: When complete resection was achieved, a substantial proportion of patients with surgically treated, early-stage LPHL experienced long-term remission and actually may have been cured. Copyright (c) 2007 American Cancer Society.

Entities:  

Mesh:

Year:  2007        PMID: 17526010     DOI: 10.1002/cncr.22762

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  20 in total

Review 1.  State of the art in the treatment of Hodgkin lymphoma.

Authors:  Peter Borchmann; Dennis A Eichenauer; Andreas Engert
Journal:  Nat Rev Clin Oncol       Date:  2012-06-12       Impact factor: 66.675

2.  Surgeon Concordance in the Assessment of Resectability for Stage IA Nodular Lymphocyte Predominant Hodgkin Lymphoma.

Authors:  Jennifer H Aldrink; Burton Appel; Joel A Kaplan; Robert E Hutchison; Cindy L Schwartz; Kara M Kelly; Kathleen McCarten; Peter F Ehrlich
Journal:  J Pediatr Hematol Oncol       Date:  2018-04       Impact factor: 1.289

Review 3.  [Update on nodular lymphocyte predominant Hodgkin's lymphoma and related lesions].

Authors:  S Hartmann; M-L Hansmann
Journal:  Pathologe       Date:  2017-02       Impact factor: 1.011

Review 4.  FDG PET/CT in children and adolescents with lymphoma.

Authors:  Regine Kluge; Lars Kurch; Françoise Montravers; Christine Mauz-Körholz
Journal:  Pediatr Radiol       Date:  2013-03-24

5.  [Treatment of low-risk pediatric lymphocyte-predominant Hodgkin lymphoma].

Authors:  Georg Mann; Wolfgang Holter
Journal:  Strahlenther Onkol       Date:  2016-11       Impact factor: 3.621

6.  Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.

Authors:  Julien Lazarovici; Peggy Dartigues; Pauline Brice; Lucie Obéric; Isabelle Gaillard; Mathilde Hunault-Berger; Florence Broussais-Guillaumot; Emmanuel Gyan; Serge Bologna; Emmanuelle Nicolas-Virelizier; Mohamed Touati; Olivier Casasnovas; Richard Delarue; Frédérique Orsini-Piocelle; Aspasia Stamatoullas; Jean Gabarre; Luc-Matthieu Fornecker; Thomas Gastinne; Fréderic Peyrade; Virginie Roland; Emmanuel Bachy; Marc André; Nicolas Mounier; Christophe Fermé
Journal:  Haematologica       Date:  2015-10-01       Impact factor: 9.941

7.  Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.

Authors:  Sven Borchmann; Erel Joffe; Craig H Moskowitz; Andrew D Zelenetz; Ariela Noy; Carol S Portlock; John F Gerecitano; Connie L Batlevi; Philip C Caron; Pamela Drullinsky; Audrey Hamilton; Paul A Hamlin; Steven M Horwitz; Anita Kumar; Matthew J Matasar; Alison J Moskowitz; Colette N Owens; M Lia Palomba; Anas Younes; David J Straus
Journal:  Blood       Date:  2019-02-15       Impact factor: 22.113

8.  Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children's Oncology Group.

Authors:  Lianna J Marks; Qinglin Pei; Rizvan Bush; Allen Buxton; Burton Appel; Kara M Kelly; Cindy L Schwartz; Debra L Friedman
Journal:  Pediatr Blood Cancer       Date:  2018-09-14       Impact factor: 3.167

9.  Impact of low-dose involved-field radiation therapy on pediatric patients with lymphocyte-predominant Hodgkin lymphoma treated with chemotherapy: a report from the Children's Oncology Group.

Authors:  Burton E Appel; Lu Chen; Allen Buxton; Suzanne L Wolden; David C Hodgson; James B Nachman
Journal:  Pediatr Blood Cancer       Date:  2012-07-27       Impact factor: 3.167

10.  Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group.

Authors:  Burton E Appel; Lu Chen; Allen B Buxton; Robert E Hutchison; David C Hodgson; Peter F Ehrlich; Louis S Constine; Cindy L Schwartz
Journal:  J Clin Oncol       Date:  2016-05-16       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.